Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy
Brief Summary: The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung cancer in comparison to a placebo plus best supportive care (a so-called placebo controlled study).


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine, Procedure: Radiotherapy | Intervention Type: BIOLOGICAL; Name: Immunotherapeutic GSK1572932A; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Cisplatin (CDDP); Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: PROCEDURE; Name: Radiotherapy; Assigned to Arm(s): Cohort 4
B: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group
C: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm

Answer: D